CAR-T for Solid Tumors: Q1 2026 Trial Readouts and the Off-the-Shelf Problem

CAR-T solid tumors trial readouts illustration showing 2026 clinical pipeline progress

CAR-T Solid Tumors: Q1 2026 Trial Readouts and the Off-the-Shelf Problem — For more than a decade, CAR-T cell therapy has been one of oncology’s most electrifying stories — and one of its most stubbornly partial ones. The technology can cure relapsed blood cancers that once carried months-long prognoses. It is less effective against the … Read more

The GLP-1 Manufacturing Race Is a Supply Chain Problem, Not a Drug Problem

GLP-1 manufacturing sterile injectable fill-finish facility and supply capacity

GLP-1 manufacturing is becoming the bottleneck that decides who can supply the next wave of obesity drugs, and capital is following the capacity. Eli Lilly committed $6B to a single manufacturing plant in Huntsville, Alabama, in December 2025 — the largest single-site pharmaceutical investment in state history. Amgen followed in April 2026 with a $900M … Read more